{"entity":{"id":"cervical-adenosquamous-carcinoma","kind":"cancer","name":"Adenosquamous carcinoma of the cervix","aka":["Adenosquamous carcinoma","Adenosquamous cervical cancer","Mixed adenocarcinoma and squamous cell carcinoma of the cervix"],"tldr":"Adenosquamous carcinoma of the cervix is an uncommon cervical cancer containing both gland-forming and squamous cancer cells. Like cervical adenocarcinoma it is caught less well by smear screening and does somewhat worse than squamous cancer stage for stage, but it is treated the same way, with surgery when early and chemoradiation when advanced.","summary":"The WHO classification of female genital tumours lists adenosquamous carcinoma among the HPV-associated cervical carcinomas, defined by both malignant glandular and squamous components. Cytology screening often fails to prevent adenocarcinoma; in a case-control study of 12,418 women with cervical cancer in England and Wales, being up to date with screening halved the odds of adenocarcinoma (odds ratio 0.46) and reduced advanced-stage adenocarcinoma more, and the paper treats adenosquamous carcinoma with adenocarcinoma (International Journal of Cancer 2016). In 148 patients with stage I to IVA adenocarcinoma or adenosquamous carcinoma treated with definitive radiotherapy, five-year relapse-free survival was 68 percent for non-bulky IB/IIA, 38 percent bulky IB/IIA, 49 percent IIB, 30 percent III and 0 percent IVA, inferior to squamous cell carcinoma, with distant failure common (Int J Radiat Oncol Biol Phys 2011).\n\nHow it differs from its parent: the parent page covers cervical cancer overall, three quarters squamous; adenosquamous carcinoma shares adenocarcinoma's screening blind spot and its worse radiotherapy outcomes, and its glandular component may raise the risk of ovarian and distant spread.\n\nHow common: no separate share in the sources read.\n\nTreatment: as cervical cancer by stage on the parent and its early and recurrent pages: radical hysterectomy for early disease, cisplatin-based chemoradiation with brachytherapy for locally advanced disease, and platinum with pembrolizumab or bevacizumab for recurrent or metastatic disease; no histology-specific trial exists.","asOf":"2026-09-24","wikipedia":"https://en.wikipedia.org/wiki/Cervical_cancer","links":[{"label":"NCI PDQ: cervical cancer treatment","url":"https://www.cancer.gov/types/cervical/treatment"},{"label":"International Journal of Cancer 2016: is cervical screening preventing adenocarcinoma and adenosquamous carcinoma of the cervix?","url":"https://doi.org/10.1002/ijc.30152"},{"label":"Int J Radiat Oncol Biol Phys 2011: outcome of adenocarcinoma and adenosquamous carcinoma of the cervix after definitive radiotherapy, 148 patients","url":"https://doi.org/10.1016/j.ijrobp.2010.02.009"}],"tags":["subtype-page","wave4","rare"],"related":["cervical","early-cervical-cancer","recurrent-metastatic-cervical-cancer","cervical-small-cell-neuroendocrine-carcinoma","vaginal-adenocarcinoma"],"cancers":[],"sections":[],"technologies":["brachytherapy"],"targets":[],"drugs":["cisplatin","pembrolizumab","bevacizumab"],"companies":[],"institutions":[],"pathways":[],"terms":["hpv-p16","chemoradiation"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"group":"gynaecologic","burden":"A minority of cervical cancers grouped with adenocarcinoma in most series; in England and Wales adenocarcinoma has become more common as squamous carcinoma declined under screening (International Journal of Cancer 2016). No separate share is in the sources read.","subtypes":["HPV-associated adenosquamous carcinoma of the cervix (the usual form)","Adenosquamous carcinoma with glassy cell features","Adenosquamous carcinoma, early stage (surgery)","Adenosquamous carcinoma, locally advanced (chemoradiation; inferior control to squamous)"],"biomarkers":["p16 and HPV status","Both glandular and squamous components on histology","FIGO stage and tumour bulk","PD-L1 for recurrent disease"],"standardOfCare":[{"setting":"All stages","approach":"Treated as cervical cancer by stage: radical hysterectomy when early, cisplatin chemoradiation with brachytherapy when locally advanced, platinum with pembrolizumab or bevacizumab when recurrent.","refs":["cervical","early-cervical-cancer","recurrent-metastatic-cervical-cancer","cisplatin","pembrolizumab","bevacizumab","brachytherapy"]}],"stateOfArt":[],"history":[],"pipeline":[],"openProblems":[],"parent":"cervical"},"route":"/cancers/cervical-adenosquamous-carcinoma/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"early-cervical-cancer","kind":"cancer","name":"Early cervical cancer and fertility-sparing surgery","route":"/cancers/early-cervical-cancer/"},{"id":"recurrent-metastatic-cervical-cancer","kind":"cancer","name":"Recurrent or metastatic cervical cancer","route":"/cancers/recurrent-metastatic-cervical-cancer/"},{"id":"cervical-small-cell-neuroendocrine-carcinoma","kind":"cancer","name":"Small cell neuroendocrine carcinoma of the cervix","route":"/cancers/cervical-small-cell-neuroendocrine-carcinoma/"},{"id":"vaginal-adenocarcinoma","kind":"cancer","name":"Vaginal adenocarcinoma (including DES-associated clear cell adenocarcinoma)","route":"/cancers/vaginal-adenocarcinoma/"}],"technology":[{"id":"brachytherapy","kind":"technology","name":"Brachytherapy","route":"/technologies/brachytherapy/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"term":[{"id":"chemoradiation","kind":"term","name":"Chemoradiation (chemoradiotherapy, CRT)","route":"/terms/chemoradiation/"},{"id":"hpv-p16","kind":"term","name":"HPV-positive (p16) head and neck cancer","route":"/terms/hpv-p16/"}]}}